HKD 17.37
−1.75%Oct 23, 2026, 10:34 UTC
Zai Lab Ltd agreed to file a registration statement to register resale of the American depositary shares sold in its private placement.
Oct 23, 2026, 10:33 UTC
Zai Lab shared first data from a global Phase 1b trial evaluating zocilurtatug pelitecan with atezolizumab, with and without carboplatin, as first-line treatment for extensive-stage small cell lung cancer.
Source:Oct 23, 2026, 02:59 UTC
Zai Lab Ltd shares fell more than 6% intraday to HK$16.71, their lowest level since August 7.
Source:Oct 23, 2026, 00:38 UTC
Zai Lab Ltd announced a private placement of 11.34 million ADSs at $22.04 each, raising approximately $250 million gross and $241 million net, with proceeds primarily supporting global clinical development of zocilurtatug pelitecan and general working capital.
Oct 21, 2026, 11:30 UTC
Zai Lab announced that it will report its third-quarter 2026 financial results and provide corporate updates on November 5, 2026, before U.S. markets open.
Source:Oct 14, 2026, 11:00 UTC
Zai Lab announced that data from the first clinical trial of its ZL-1503 antibody will be presented at the ACAAI 2026 Annual Scientific Meeting in Phoenix.
Source:Sep 25, 2026, 01:38 UTC
US-listed Chinese stocks weakened, with the Nasdaq Golden Dragon China Index down 0.67% and names including Hichain Securities, Yatsen E-Commerce, Zhineng Weilai, So-Young, Zai Lab, Baidu and Pinduoduo declining.
Source:Sep 23, 2026, 09:08 UTC
Goldman Sachs reduced its long position in Zai Lab Limited from 5.07% to 4.97%, as disclosed by Hong Kong Exchanges and Clearing on September 18, 2026.
Source:Aug 9, 2026, 11:55 UTC
Zai Lab announced that its DLL3-targeting antibody-drug conjugate zociluratug pelitecan (zoci) has advanced from an Investigational New Drug application to global Phase 3 development in under two years, with the DLLEVATE study evaluating it in second-line and later extensive-stage small cell lung cancer.
Source:Aug 6, 2026, 10:30 UTC
Zai Lab Limited announced its financial results for the second quarter of 2026, along with recent product highlights and corporate updates.
Aug 3, 2026, 11:00 UTC
The U.S. FDA granted Orphan Drug Designation to Zai Lab's DLL3-targeting ADC zocilurtatug pelitecan for the treatment of neuroendocrine carcinomas.
Source:Jun 9, 2026, 00:34 UTC
China's NMPA approved Zai Lab's Biologics License Application for TIVDAK (tisotumab vedotin for injection) to treat recurrent or metastatic cervical cancer.
Source: